in vitro News and Research

RSS

Key scientific work in Cardio3 BioSciences' C-Cure stem cell heart failure treatment published in JACC

Cardio3 BioSciences, a leading Belgian biotechnology company specialising in regenerative therapies for the treatment of cardiovascular disease, today announces that the key scientific work underlying its lead pharmaceutical product C-Cure(R), a revolutionary stem cell treatment for heart failure, has been published in the Journal of the American College of Cardiology (JACC). The findings were described as "landmark work" in the accompanying editorial in today's publication.

17 Aug 2010

Human adult stem cells can regenerate damaged heart tissue: Research

Mayo Clinic investigators, with Belgian collaborators, have demonstrated that rationally "guided" human adult stem cells can effectively heal, repair and regenerate damaged heart tissue. The findings called "landmark work" in an accompanying editorial appear in today's Journal of the American College of Cardiology.

17 Aug 2010

IVAX Diagnostics second quarter 2010 operating expenses decrease 11.9%

IVAX Diagnostics, Inc., a fully integrated in vitro diagnostics company, reports its financial results for the quarter ended June 30, 2010.

17 Aug 2010

Majority of women support single woman using IVF treatment to conceive, survey finds

A recent survey of American women aged 25-45 that gauged attitudes toward In Vitro Fertilization found that 83% of these women support a single woman using IVF to conceive if she is emotionally and financially able to care for the child.

16 Aug 2010

Involuntary childlessness affects couples more negatively than previously reported

Test-tube fertilisation is the reason why more couples than previously now have the chance to become biological parents. However, the path to achieving this can be laborious and, for some, the treatment is unsuccessful. A thesis from the University of Gothenburg, Sweden, indicates that people are more negatively affected than previously reported in studies of involuntary childlessness.

16 Aug 2010

Researchers develop method to predict lifetime of implants

Extra-hard coatings made from diamond-like carbon (DLC) extend the operating lifetime of tools and components. In artificial joints, however, these coatings often fail because they detach. Empa researchers found out why - and developed methods to both make the interface between the DLC layer and the metal underneath corrosion-resistant and to predict the lifetime of the implants.

16 Aug 2010

China Medical Technologies first-quarter fiscal 2010 revenues decrease 10.9% to RMB186.2 million

China Medical Technologies, Inc., a leading China-based advanced in-vitro diagnostic company, today announced its unaudited financial results for the first fiscal quarter ended June 30, 2010.

16 Aug 2010

U.S. FDA purchases more licenses to Simulations Plus' DDDPlus software

Simulations Plus, Inc., a leading provider of software for pharmaceutical discovery and development, today announced that it has received a purchase order from the U.S. Food and Drug Administration to expand the number of licenses for the Company's DDDPlus™ simulation software.

13 Aug 2010

Researchers develop new implantable metamaterials to destroy cancerous tissue

The research, reported online July 21, 2010, in the journal Advanced Materials, provides a promising path towards the development of a new class of metamaterial-inspired implantable biosensors and biodetectors.Metamaterials are artificial electromagnetic composites, typically made of highly conducting metals, whose structures respond to electromagnetic waves in ways that atoms in natural materials do not. The most futuristic metamaterials would absorb all light, to create heat to destroy cancerous tissue, or bend light completely around an object, rendering that object invisible-an imaginary delight for fans of science fiction or spy novels.

13 Aug 2010

A*STAR's Singapore Immunology Network, Institut M-rieux and bioM-rieux partner in TB research

An investment of S$3 million is being pumped into tuberculosis (TB) research by A*STAR's Singapore Immunology Network (SIgN), bioindustrial group Institut M-rieux and its in vitro diagnostics company bioM-rieux. The project, which involves setting up a joint laboratory in Biopolis, Singapore aims to investigate and identify novel biomarkers that could allow early identification of individuals at risk of TB disease development and disease reactivation. This could lead to better diagnosis and treatment for the highly contagious disease.

13 Aug 2010

Aeterna Zentaris second-quarter revenues decrease to $5.6 million

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrinology, today reported financial and operating results for the second quarter ended June 30, 2010.

12 Aug 2010

Evotec revenues for first-half of 2010 increase 33% to € 25.0 m

Evotec AG today reported financial results and corporate updates for the first half of 2010.

12 Aug 2010

Advanced Life Sciences second-quarter net loss decreases to $2.1 million

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced its financial results for the second quarter ended June 30, 2010.

11 Aug 2010

Rxi Pharmaceuticals second-quarter net loss decreases to $2.1 million

RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutic discovery and development, today reported its financial results for the second quarter ended June 30, 2010.

11 Aug 2010

Tamir Biotechnology's three compounds effective show potential for yellow fever

Tamir Biotechnology, Inc.(formerly Alfacell Corporation) announced today that scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID) confirmed that testing of three of our company's compounds showed in vitro results rarely seen before by the U.S. government for yellow fever.

11 Aug 2010

Protagen granted Notice of Allowance in Japan for key method patent for identifying and selecting clones

Protagen AG, a specialist for in-vitro diagnostics and GMP-compliant protein analysis, announced today that it received a Notice of Allowance by the Japanese Patent Office stating a favourable decision for the patent application 2000-547262 developed at the Max-Planck Institute for Molecular Genetics in Berlin, Germany. This patent claims broadly a method for identifying and selecting clones relating to the basic UNIclone® technology and is already granted in Europe with the publication number EP1073770 B1.

11 Aug 2010

Quick-Med develops new NIMBUS Advanced Active prototype wound dressing

Quick-Med Technologies, Inc. announced today the development of a new prototype wound dressing, NIMBUS® Advanced Active, developed as part of ongoing research currently being funded by the U.S. Army Medical Research and Material Command under a $900,000 Small Business Innovation Research (SBIR) grant. NIMBUS was competitively selected by the U.S. Army for evaluation in the healing of vesicant injuries, and this new dressing is the first "active" wound healing product developed by Quick-Med.

10 Aug 2010

Analysis finds no evidence that inclusion of retinyl palmitate in sunscreens can cause cancer

Despite previous concerns about the cancer-causing potential of sunscreens containing retinyl palmitate (vitamin A), an independent analysis published online in the Journal of the American Academy of Dermatology determined that there is no evidence that the inclusion of retinyl palmitate in sunscreens can cause cancer in humans.

10 Aug 2010

Epitherix identifies potent and selective multiple chemical scaffolds against colorectal carcinoma

Epitherix, LLC, a privately held company focused on the discovery and development of novel Wnt pathway small molecule inhibitors for epithelial and leukemic cancers, today announced that it has identified multiple chemical scaffolds that are potent and selective against colorectal carcinoma. "We're very encouraged by our in vitro and in vivo data, especially considering the difficulty in drugging this pathway to date," said Dr. Osman Kibar, CEO of Epitherix.

10 Aug 2010

Alnylam Pharmaceuticals reports significant progress in discovery of novel technologies for systemic delivery of RNAi therapeutics

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, and collaborators from the Massachusetts Institute of Technology (MIT), The University of British Columbia (UBC), AlCana Technologies, Inc., and Tekmira Pharmaceuticals Corporation, presented results from multiple ongoing research efforts regarding the discovery of novel technologies for the systemic delivery of RNAi therapeutics.

10 Aug 2010

in vitro News and Research

Key scientific work in Cardio3 BioSciences' C-Cure stem cell heart failure treatment published in JACC

Human adult stem cells can regenerate damaged heart tissue: Research

IVAX Diagnostics second quarter 2010 operating expenses decrease 11.9%

Majority of women support single woman using IVF treatment to conceive, survey finds

Involuntary childlessness affects couples more negatively than previously reported

Researchers develop method to predict lifetime of implants

China Medical Technologies first-quarter fiscal 2010 revenues decrease 10.9% to RMB186.2 million

U.S. FDA purchases more licenses to Simulations Plus' DDDPlus software

Researchers develop new implantable metamaterials to destroy cancerous tissue

A*STAR's Singapore Immunology Network, Institut M-rieux and bioM-rieux partner in TB research

Aeterna Zentaris second-quarter revenues decrease to $5.6 million

Evotec revenues for first-half of 2010 increase 33% to € 25.0 m

Advanced Life Sciences second-quarter net loss decreases to $2.1 million

Rxi Pharmaceuticals second-quarter net loss decreases to $2.1 million

Tamir Biotechnology's three compounds effective show potential for yellow fever

Protagen granted Notice of Allowance in Japan for key method patent for identifying and selecting clones

Quick-Med develops new NIMBUS Advanced Active prototype wound dressing

Analysis finds no evidence that inclusion of retinyl palmitate in sunscreens can cause cancer

Epitherix identifies potent and selective multiple chemical scaffolds against colorectal carcinoma

Alnylam Pharmaceuticals reports significant progress in discovery of novel technologies for systemic delivery of RNAi therapeutics

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News